Posted by Michael Wonder on 14 Oct 2017
Prometic announces FDA acceptance of its biologics license application for plasminogen (Ryplazim)
13 October 2017 - Ryplazim previously granted fast track, rare paediatric disease and orphan drug designations by U.S. FDA.
Prometic Life Sciences today announced that the U.S FDA has accepted its biologics license application for its plasminogen replacement therapy (Ryplazim) having granted a priority review status and set a Prescription Drug User Fee Act action date for 14 April 2018.
